• Adaptive Biotechnologies Chief Commercial Officer, MRD Susan Bobulsky sold 487 common shares on July 1 at USD 22.
• Bobulsky held 406,288 common shares following the transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001820885-26-000014), on July 06, 2026, and is solely responsible for the information contained therein.